Abstract:BackgroundColorectal cancer is the third most common cancer. Involvement of prostaglandin (PG) system in the pathogenesis of colorectal cancer has been suggested from clinical studies demonstrating therapeutic effect of NSAIDs including aspirin or selective COX-2 inhibitors. However, mechanisms on how PG regulates inflammatory responses leading to colorectal cancer development remain obscure. Further, careful attention is needed to use these drugs for a long time because of adverse effects due to non-specific inhibition of physiological PG production in addition to pathological one, making the development of alternatives to aspirin important. Recent studies using mouse model of colitis-associated colon cancer, azoxymethane (AOM)-dextran sodium sulfate (DSS) model, have revealed some of the mechanisms on how PG regulates inflammation in lesions and proposed PG receptor as a therapeutic target.Main body of abstractAmong each PG receptor subtype examined, prostaglandin E receptor 2 (EP2) signaling specifically contributes to colorectal cancer formation and inflammation in lesions of AOM-DSS model. EP2 is expressed in neutrophils, infiltrated major inflammatory cells, and tumor-associated fibroblasts (TAFs) in the tumor stroma of this mouse model and also in clinical specimen from ulcerative colitis-associated colorectal cancer. Bone marrow transfer experiments between wild-type and EP2-deficient mice have confirmed the involvement of EP2 signaling in these two types of cells in the pathogenesis of the disease. EP2 signaling in both types of cells regulates the transition to and maintenance of inflammation in multiple steps to shape the tumor microenvironment which contributes to trigger and promote colorectal cancer. In this process, PGE2-EP2 signaling synergizes with TNF-α to amplify TNF-α-induced inflammatory responses, forms a positive feedback loop involving COX-2-PGE2-EP2 signaling to exacerbate PG-mediated inflammation once triggered, and alternates active cell populations participating in inflammation through forming self-amplification loop among neutrophils. Thus, EP2 signaling functions as a node of inflammatory responses in the tumor microenvironment. Based on such a notion, EP2 can become a strong candidate for therapeutic target of colorectal cancer treatment. Indeed, in AOM-DSS model, a selective EP2 antagonist, PF-04418948, potently suppresses colorectal tumor formation.Short conclusionPGE2-EP2 signaling functions as a node of chronic inflammation which shapes the tumor microenvironment and thus is a strong candidate of target for the chemoprevention of colorectal cancer.

Prostaglandin E2–EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion

Prostaglandin E 2 Receptor Subtype 2 (EP2) Regulates Microglial Activation and Associated Neurotoxicity Induced by Aggregated Α-Synuclein

Prostaglandin E2 Signal Inhibits T Regulatory Cell Differentiation During Allergic Rhinitis Inflammation Through EP4 Receptor.

The Signaling Pathway of PGE2 and Its Regulatory Role in T Cell Differentiation.

Prostaglandin E2-EP2 signaling as a node of chronic inflammation in the colon tumor microenvironment

EP2 Receptor Signaling Pathways Regulate Classical Activation of Microglia*

Prostaglandin E2 Inhibits Group 2 Innate Lymphoid Cell Activation and Allergic Airway Inflammation Through E-Prostanoid 4-Cyclic Adenosine Monophosphate Signaling

Prostaglandin E2 inhibits the differentiation of T regulatory cells by Peroxisome Proliferator-Activated Receptor-Gamma during allergic rhinitis

Prostaglandins E2 Signal Mediated by Receptor Subtype EP2 Promotes IgE Production in Vivo and Contributes to Asthma Development.

Suppression of Inflammation with Conditional Deletion of the Prostaglandin E2 EP2 Receptor in Macrophages and Brain Microglia

Activation of EP2 receptor suppresses poly(I: C) and LPS‐mediated inflammation in primary microglia and organotypic hippocampal slice cultures: Contributing role for MAPKs

[Prostaglandin(pg) E2 in Regulation of Immunity and Inflammatory Diseases].

Prostaglandin D2 signaling in dendritic cells is critical for the development of EAE

E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis

Prostanoids and inflammation: a new concept arising from receptor knockout mice

Abstract A019: Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells infiltrating human tumor

Prostaglandin E Receptor 4 (EP4) Promotes Colonic Tumorigenesis

Prostaglandin E 2 promotes intestinal inflammation via inhibiting microbiota-dependent regulatory T cells

PPARγ As an E3 Ubiquitin-Ligase Impedes Phosphate-Stat6 Stability and Promotes Prostaglandins E2-Mediated Inhibition of IgE Production in Asthma

Exploring the roles of prostanoids, leukotriens, and dietary fatty acids in cutaneous inflammatory diseases: Insights from pharmacological and genetic approaches

Impaired TNF/TNFR2 Signaling Enhances Th2 and Th17 Polarization and Aggravates Allergic Airway Inflammation.